Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life
Authors
- Ulrich Mrowietz (ORCID: https://orcid.org/0000-0002-9539-0712)
- Matthias Augustin (ORCID: https://orcid.org/0000-0002-4026-8728)
- Curdin Conrad (ORCID: https://orcid.org/0000-0002-2547-3440)
- J.M. Carrascosa (ORCID: https://orcid.org/0000-0003-4266-0771)
- D. Jullien (ORCID: https://orcid.org/0000-0002-2995-7928)
- Stephen Colgan
- Juliet N. Barker (ORCID: https://orcid.org/0000-0002-9030-183X)
- Hamid Amouzadeh
- Jyotsna Reddy
- Henry Zou
Institutions
- Amgen (United States) (US)
- Universität Hamburg (DE)
- King's College London (GB)
- Hospices Civils de Lyon (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- Hospital Universitari Germans Trias i Pujol (ES)
- Clinical Research Center Kiel (DE)
- University of Lausanne (CH)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1007/s13555-025-01389-z
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Amgen